Bio-Rad Laboratories, Inc. BIOB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.02B | 222.40M | 168.80M | 759.90M | -675.90M |
| Total Depreciation and Amortization | 165.70M | 168.70M | 168.20M | 165.40M | 162.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.06B | -20.10M | 113.10M | -665.50M | 1.20B |
| Change in Net Operating Assets | 337.40M | 121.60M | 60.30M | 272.40M | -197.70M |
| Cash from Operations | 468.10M | 492.60M | 510.40M | 532.20M | 491.50M |
| Capital Expenditure | -139.00M | -139.50M | -153.20M | -157.60M | -154.70M |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 200.00K | 100.00K | 100.00K |
| Cash Acquisitions | 1.10M | -700.00K | -218.50M | -218.50M | -218.50M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -202.10M | -96.90M | 85.70M | 186.30M | 187.10M |
| Cash from Investing | -340.00M | -237.10M | -285.80M | -189.70M | -186.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -600.00K | -500.00K | -500.00K | -500.00K | -300.00K |
| Issuance of Common Stock | 15.10M | 14.90M | 14.90M | 15.80M | 15.80M |
| Repurchase of Common Stock | -84.90M | -135.70M | -244.40M | -298.50M | -298.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 500.00K | 500.00K | 500.00K | -- | -30.00M |
| Cash from Financing | -69.90M | -120.80M | -229.50M | -283.20M | -312.70M |
| Foreign Exchange rate Adjustments | 10.70M | 12.40M | -9.20M | -16.90M | -6.80M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.90M | 147.10M | -14.10M | 42.40M | -14.00M |